Novartis is paying $54 million upfront to buy ... development of gene therapies for neurological diseases to date." Spain has agreed to reimburse Orchard Therapeutics' ex vivo gene therapy for ...

Novartis has axed development of its mid-stage ... analysis midway through a phase 2 trial showed it was likely to fail. Spain’s Almirall is another company hoping to take on Sanofi – it ...

respectively Over 5,000 patients treated to date Initiated commercial production of CARVYKTI ® at a Novartis production facility Spain's national health system approved reimbursement for CARVYKTI ...